Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Medicine Quality Research Group organised a multidisciplinary hybrid meeting at Keble College, Oxford, July 3 to 6, for the FORESFA project ‘Forensic epidemiology and impact of substandard and falsified antimicrobials on public health’, funded by a Wellcome Collaborative Award.

FORESFA conference 2022 Oxford group photo

FORESFA

Fifty-three colleagues from 12 countries, including pharmacists, forensic geneticists and chemists, modelers, sociologists, data scientists, informaticians, microbiologists, criminologists, public engagement specialists and food safety scientists, with national and international organisation representatives, met for vibrant discussions and planning for the project.

Those present in person went for after lunch walks, including to the Sir William Dunn School of Pathology blue plaque commemorating where penicillin was first brewed up to administer to patients.

VIE

The Group continued with another, overlapping, multidisciplinary hybrid meeting at Keble, from July 6 to 8, to discuss the Vaccine Identity Evaluation (VIE) project, that is evaluating devices for screening for substandard and falsified (SF) vaccines in supply chains.

The VIE team, of the CTMGH, Department of Biochemistry and Department of Chemistry, Oxford and the Science and Technology Facilities Council’s Rutherford Appleton Laboratory (RAL), were joined by sixty colleagues from eleven countries including vaccine and device manufacturers, medicines regulators, virologists, chemists, physicists, forensic scientists, data scientists, police and investigators, sociologists and translational research experts.

Pilot data were discussed and much progress made on future collaborative plans with a vision to bring about a step change in our ability to detect SF vaccines. The diverse devices were demonstrated at RAL and in Biochemistry and Chemistry.

Similar stories

Incomplete reporting of COVID-19 disease severity criteria compromises meta-analysis

Patients affected by COVID-19 should be treated according to the severity of their disease. However, not all key national or international organisations define severity in the same way. This imprecision in severity assessment compromises the validity of some therapeutic recommendations. Using individual patient data would better guide and improve therapeutic recommendations for COVID-19.

A multi-country study of monkeypox being launched – first cases enrolled in Geneva

Researchers have launched a new study to improve our understanding of monkeypox disease. The first patients have now been recruited at Hôpitaux Universitaires de Genève (HUG) in Switzerland

Pandemic Sciences Institute formally launched in Oxford

The University of Oxford’s Pandemic Sciences Institute (PSI) has been formally launched at a two-day event at the Blavatnik School of Government, at which the lead researchers set out its direction and strategy for the next five years.The PSI will draw together academics and experts from across the University to build a multi-disciplinary institute focused on reducing the risk from infectious threats through science, innovation and building global preparedness.

Field evaluation of EasyScan GO: a digital malaria microscopy device

Microscopic examination of Giemsa-stained blood films is key to quantifying and detecting malaria parasites but there can be difficulties in ensuring both a high-quality manual reading and inter-reader reliability. The EasyScan GO was developed as a potential solution to this, a microscopy device using machine-learning-based image analysis for automated parasite detection and quantification.

Registration is open for The Global Health Network Conference 2022

To tackle disease we need evidence to be generated through every type of health research study. This conference aims to bring together health research teams, organisations, health-workers, policy makers and practitioners to explore together how health research can be embedded into every healthcare setting. Join us at The Global Health Network Conference 2022 at the University of Cape Town, South Africa, 24 – 25 November 2022

The inside story of Recovery: how the world’s largest COVID-19 trial transformed treatment – and what it could do for other diseases

Two years ago, the Recovery trial transformed the care of COVID patients with its dexamethasone announcement. Within four hours, the steroid was included in NHS treatment recommendations. Almost overnight, treatment of COVID patients around the world changed completely. It has been estimated that dexamethasone may have saved a million lives in the first nine months following the announcement. Recovery is a groundbreaking scientific machine which, from the outset, moved at unprecedented speed. In the first 100 days alone, the trial produced three groundbreaking results that would completely reshape COVID care.